GLPwatch
A New Drug for Obesity: Tirzepatide.
Endocr Metab Immune Disord Drug Targets · 2025
Last updated 2026-05-28Tirzepatide is a new drug approved for obesity that works on two hormones, GIP and GLP-1, to help control blood sugar and promote weight loss. In studies, it has shown better results for weight loss compared to drugs that only target GLP-1.
AI summary of the abstract below.
| Journal | Endocr Metab Immune Disord Drug Targets, 2025 |
|---|---|
| Citations | 3 |
| Molecules | tirzepatide |
| Conditions studied | Obesity |
Abstract
Obesity is now recognised as an emerging public health problem across the globe. Its incidence has been growing in the last two decades. Furthermore, as per the obesity treatment guidelines, a comprehensive approach that incorporates behavioural treatment, medications, lifestyle modifications, and/or bariatric surgery is the best way to manage weight. A novel dual agonist of Glucose-dependent insulinotropic peptide (GIP) and Glucagon-like peptide -1 (GLP- 1) receptors, Tirzepatide, was recently approved for the management of obesity. Tirzepatide manages blood sugar levels and enhances weight loss more than GLP-1 receptor agonists.
Verbatim abstract via PubMed 38994609 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.